Syndax Presents New Revuforj (revumenib) Data In Relapsed/Refractory mNPM1 And NUP98r Acute Leukemia From AUGMENT-101 Trial At EHA 2025

26% (20/77) CR+CRh rate and 48% (37/77) ORR in efficacy-evaluable pivotal R/R mNPM1 AML population.

– Robust responses observed across subgroups, regardless of co-mutations, number of prior lines of therapy, or prior venetoclax, within efficacy-evaluable pivotal R/R mNPM1 AML population.

– 60% (3/5) ORR in Ph 1 patients with R/R NUP98r AML.